FDA Updates Temozolomide Prescribing Information in Brain Cancer

News
Article

Prescribing information has been updated to include temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma or refractory anaplastic astrocytoma.

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The FDA has approved updated labeling for temozolomide (Temodar) in brain cancer, according to a press release from the organization.1

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The press release noted that the approved indication for temozolomide in adult patients with newly diagnosed glioblastoma, given concomitantly with radiotherapy and as maintenance therapy, remains the same. Temozolomide was originally approved by the FDA under this indication in March 2005.2 Temozolomide was approved for intravenous use in 1999.3

The label update also includes the dosing regimen for patients with newly diagnosed glioblastoma and refractory anaplastic astrocytoma. For temozolomide given as capsules, there is an increase of exposure risk from opened capsules. Additionally, the patient counseling information section has been revised.

The updated labeling comes under the Project Renewal program with the Oncology Center of Excellence. This program is designed to revise label information for older drugs in the oncology space so that all information is up-to-date and relevant.

References

  1. FDA approves new and updated indications for temozolomide under Project Renewal. News release. FDA. September 14, 2023. Accessed September 14, 2023. https://bit.ly/3LnH9fS
  2. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Ddug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11(19 Pt 1):6767-6771. doi:10.1158/1078-0432.CCR-05-0722
  3. Temozolomide. Prescribing information. Merck; 2023. Accessed September 14, 2023. https://bit.ly/46uUH1p
Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Related Content
Vorasidenib Improves PFS, Shows Tumor Reduction in IDH1/2+ Glioma | Image Credit: © Dr_Microbe - stock.adobe.com.

Vorasidenib Improves PFS, Shows Tumor Reduction in IDH1/2+ Glioma

Kristi Rosa
November 29th 2024
Article

Treatment with vorasidenib also confers better seizure control than placebo in the phase 3 INDIGO study.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

TTFields Plus Temozolomide/Pembrolizumab Controls Tumors in Glioblastoma

Ariana Pelosci
November 11th 2024
Article

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial

Nader Sanai, MD
September 23rd 2024
Podcast

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.

PET Imaging Agent Earns FDA Priority Review in Recurrent Glioma

Russ Conroy
October 25th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.

MTX110 May Show Survival Benefits in Recurrent Glioblastoma

Russ Conroy
October 20th 2024
Article

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.